Table 2.
Summary of the main results.
| Population | N1 | T1DM: pooled effect size IDeg : IGlar (95% confidence interval) |
N2 | T2DM: pooled effect size IDeg : IGlar (95% confidence interval) |
N (N1 + N2) | Overall: pooled effect size IDeg : IGlar (95% confidence interval) |
|---|---|---|---|---|---|---|
| Items | ||||||
| Change of HbA1c | 2342 | MD = 0.05% (−0.01%, 0.10%) | 13,986 | MD = 0.04% (0.00, 0.07%)# | 16,328 | MD = 0.04% (0.01%, 0.07%)# |
| Change of FPG | 2302 | MD = −0.84 (−1.18, −0.51)# | 12,544 | MD = −0.34 (−0.45, −0.23)# | 14,846 | MD = −0.41 (−0.54, −0.28)# |
| Change of body weight | 2342 | MD = −0.04 (−0.35, 0.26) | 13,986 | MD = 0.05 (−0.11, 0.22) | 16,328 | MD = 0.03 (−0.11, 0.18) |
| Participants achieved HbA1c levels of <7% | 629 | RR = 0.93, (0.75, 1.15) | 4754 | RR = 0.96, (0.90, 1.03) | 5383 | RR = 0.96, (0.90, 1.02) |
| Overall hypoglycemia | 2302 | RR = 0.97 (0.87, 1.08) | 6349 | RR = 0.82 (0.73, 0.92)# | 8651 | RR = 0.88 (0.81, 0.96)# |
| Nocturnal hypoglycemia | 2302 | RR = 0.74 (0.68, 0.81)# | 6349 | RR = 0.74 (0.66, 0.82)# | 8651 | RR = 0.74 (0.69, 0.79)# |
| Adverse events | 2036 | OR = 0.96 (0.78, 1.19) | 13,590 | OR = 0.94 (0.87, 1.01) | 15,626 | OR = 0.94 (0.88, 1.01) |
| Serious adverse events | 2214 | OR = 0.89 (0.67, 1.18) | 13,590 | OR = 0.95, (0.87, 1.03) | 15,804 | OR = 0.95 (0.87, 1.02) |
| Adverse events possibly/probably related to the trial product | 2036 | OR = 1.24 (0.93, 1.64) | 5496 | OR = 1.05 (0.86, 1.29) | 7532 | OR = 1.11 (0.94, 1.31) |
IDeg: insulin degludec; IGlar: insulin glargine; N1: number of patients with T1DM; N2: number of patients with T2DM; N: number of patients; T1DM: type 1 diabetes mellitus; T2DM: type 2 diabetes mellitus; MD: mean difference; RR: risk ratio; OR: odds ratio. #p < 0.05.